PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) said it has successfully concluded its cannabinoid Sol-gel delivery program which looked at methods of delivering cannabinoid extracts to the central nervous system using soluble gels.
PreveCeutical’s chief science officer Dr Mak Jawadekar called the completion of the program a “very significant milestone” for the Vancouver-based company.
“We are very excited about the therapeutic opportunities that will be derived from the program and look forward to progressing them through proof of concept studies,” Jawadekar said in a statement.
Soluble gels can be a safer, more reliable drug delivery agent for treatments like CBDs that are rapidly metabolized or would benefit from direct nose-to-brain delivery. Cannabinoids are generating interest in the medical community to treat a variety of central nervous system disorders such as neuropathic pain and multiple sclerosis.
PreveCeutical said it is planning to develop lead cannabinoid formulations that could provide therapies to address central nervous system disorders and has plans to commercialize the drugs following the conclusion of clinical trials.
The firm will provide more information when it receives the final Sol-gel program report from UniQuest Pty Limited, which will allow PreveCeutical to file patents related to the program.
PreveCeutical recently announced it is working on an extension of its cannabis sol-gel nasal program to address the coronavirus (COVID-19) pandemic, focusing on the expedited development of a CBD sol-gel to potentially reduce the possibility of coronavirus infections.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas